STOCK TITAN

PDS Biotech Announces 36-Month Overall Survival Rate of 84.4% in Locally Advanced Cervical Cancer Patients Treated with Versamune® HPV and Chemoradiation

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Positive)
Tags

PDS Biotechnology (PDSB) announced updated data from the IMMUNOCERV Phase 2 clinical trial evaluating Versamune® HPV with chemoradiation for locally advanced cervical cancer. Key highlights include:

- 36-month overall survival (OS) rate of 84.4% for all patients, and 100% for patients receiving all five doses
- 36-month progression-free survival (PFS) rate of 74.9% for all patients, and 100% for patients receiving all five doses
- Complete metabolic response achieved in 88% of patients
- Versamune® HPV appeared safe and well-tolerated

The trial enrolled 17 high-risk patients with large tumors. Historical data show 36-month OS and PFS rates of approximately 64% and 61%, respectively, with chemoradiation alone. The results suggest potential efficacy of Versamune® HPV in combination with standard-of-care for locally advanced cervical cancer treatment.

PDS Biotechnology (PDSB) ha annunciato dati aggiornati dal trial clinico di Fase 2 IMMUNOCERV che valuta Versamune® HPV in combinazione con chemoradioterapia per il cancro cervicale localmente avanzato. I punti salienti includono:

- Tasso di sopravvivenza generale (OS) a 36 mesi del 84,4% per tutti i pazienti e del 100% per i pazienti che hanno ricevuto tutte e cinque le dosi
- Tasso di sopravvivenza libera da progressione (PFS) a 36 mesi del 74,9% per tutti i pazienti e del 100% per i pazienti che hanno ricevuto tutte e cinque le dosi
- Risposta metabolica completa raggiunta in 88% dei pazienti
- Versamune® HPV è risultato sicuro e ben tollerato

Lo studio ha arruolato 17 pazienti ad alto rischio con tumori di grandi dimensioni. Dati storici mostrano tassi di OS e PFS a 36 mesi di circa il 64% e il 61%, rispettivamente, con solo chemoradioterapia. I risultati suggeriscono una potenziale efficacia di Versamune® HPV in combinazione con il trattamento standard per il cancro cervicale localmente avanzato.

PDS Biotechnology (PDSB) anunció datos actualizados del ensayo clínico de Fase 2 IMMUNOCERV que evalúa Versamune® HPV junto con la quimiorradioterapia para el cáncer cervical localmente avanzado. Los puntos destacados incluyen:

- Tasa de supervivencia general (OS) a 36 meses del 84.4% para todos los pacientes y del 100% para los pacientes que recibieron las cinco dosis
- Tasa de supervivencia libre de progresión (PFS) a 36 meses del 74.9% para todos los pacientes y del 100% para los pacientes que recibieron las cinco dosis
- Respuesta metabólica completa lograda en 88% de los pacientes
- Versamune® HPV se mostró seguro y bien tolerado

El ensayo incluyó a 17 pacientes de alto riesgo con tumores grandes. Los datos históricos muestran tasas de OS y PFS a 36 meses de aproximadamente 64% y 61%, respectivamente, solo con quimiorradioterapia. Los resultados sugieren una posible eficacia de Versamune® HPV en combinación con el tratamiento estándar para el cáncer cervical localmente avanzado.

PDS Biotechnology (PDSB)는 국소 진행 자궁경부암에 대한 화학 방사선 요법과 함께 Versamune® HPV를 평가하고 있는 IMMUNOCERV 2단계 임상 시험의 업데이트된 데이터를 발표했습니다. 주요 하이라이트는 다음과 같습니다:

- 모든 환자의 36개월 전체 생존율(OS) 84.4%, 모든 다섯 번의 용량을 받은 환자의 생존율은 100%
- 모든 환자의 36개월 진행 없는 생존율(PFS) 74.9%, 모든 다섯 번의 용량을 받은 환자의 생존율은 100%
- 88%의 환자에서 완전 대사 반응이 달성됨
- Versamune® HPV는 안전하고 잘 견디는 것으로 보임

이 시험은 큰 종양을 가진 17명의 고위험 환자를 등록했습니다. 역사적 데이터는 단독 화학 방사선 요법으로 36개월 OS 및 PFS 비율이 각각 약 64%61%임을 보여줍니다. 결과는 국소 진행 자궁경부암 치료를 위한 표준 치료와의 조합에서 Versamune® HPV의 잠재적인 효능을 시사합니다.

PDS Biotechnology (PDSB) a annoncé des données mises à jour de l'essai clinique de phase 2 IMMUNOCERV évaluant Versamune® HPV associé à la chimioradiothérapie pour le cancer du col de l'utérus localement avancé. Les points clés incluent :

- Taux de survie global (OS) à 36 mois de 84,4% pour tous les patients, et de 100% pour les patients ayant reçu les cinq doses
- Taux de survie sans progression (PFS) à 36 mois de 74,9% pour tous les patients, et de 100% pour les patients ayant reçu les cinq doses
- Réponse métabolique complète obtenue chez 88% des patients
- Versamune® HPV a montré qu'il est sûr et bien toléré

L'essai a inclus 17 patients à haut risque avec de grandes tumeurs. Les données historiques montrent des taux d'OS et de PFS à 36 mois d'environ 64% et 61%, respectivement, avec seulement la chimioradiothérapie. Les résultats suggèrent une efficacité potentielle de Versamune® HPV en combinaison avec le traitement standard pour le cancer du col de l'utérus localement avancé.

PDS Biotechnology (PDSB) hat aktualisierte Daten aus der IMMUNOCERV Phase-2-Studie veröffentlicht, die Versamune® HPV in Kombination mit Chemoradiation bei lokal fortgeschrittenem Gebärmutterhalskrebs bewertet. Zu den wichtigsten Ergebnissen gehören:

- Die 36-Monats-Gesamtüberlebensrate (OS) beträgt 84,4% für alle Patienten und 100% für Patienten, die alle fünf Dosen erhielten
- Die 36-Monats-Progressionsfreien Überlebensrate (PFS) beträgt 74,9% für alle Patienten und 100% für Patienten, die alle fünf Dosen erhielten
- Eine vollständige metabolische Antwort wurde bei 88% der Patienten erreicht
- Versamune® HPV schien sicher und gut verträglich zu sein

Die Studie umfasste 17 hochriskante Patienten mit großen Tumoren. Historische Daten zeigen 36-Monats-OS- und PFS-Raten von etwa 64% bzw. 61% nur mit Chemoradiation. Die Ergebnisse deuten auf eine potenzielle Wirksamkeit von Versamune® HPV in Kombination mit der Standardbehandlung für lokal fortgeschrittenen Gebärmutterhalskrebs hin.

Positive
  • 36-month overall survival rate of 84.4%, significantly higher than historical data of 64%
  • 100% overall survival and progression-free survival rates in patients receiving all five doses
  • 88% of patients achieved complete metabolic response
  • Versamune® HPV demonstrated a promising safety profile with minimal toxicity
Negative
  • None.

Insights

The IMMUNOCERV Phase 2 trial results for Versamune® HPV in locally advanced cervical cancer are highly promising. The 36-month overall survival rate of 84.4% significantly outperforms historical data of 64% for standard chemoradiation. Even more impressive is the 100% survival rate for patients receiving all five doses, suggesting a dose-dependent effect.

The 88% complete metabolic response rate indicates strong tumor-killing activity. Safety appears favorable, with injection site reactions as the primary side effect. These results position Versamune® HPV as a potential game-changer in cervical cancer treatment, addressing an unmet need for HPV-targeted therapies.

However, the small sample size (17 patients) and single-arm design limit definitive conclusions. A larger, randomized trial is needed to confirm efficacy. If validated, this could represent a significant advance in treating this challenging cancer type, potentially improving outcomes for thousands of patients annually.

The IMMUNOCERV trial results are indeed encouraging for locally advanced cervical cancer patients. The 100% 36-month overall and progression-free survival rates in fully treated patients are remarkable, especially considering the high-risk nature of the cohort with tumors ≥5 cm.

The safety profile appears manageable, with injection site reactions being the primary concern. This is relatively benign compared to the toxicities often associated with cancer therapies. The combination with standard chemoradiation suggests Versamune® HPV could potentially be integrated into existing treatment protocols without significant additional burden to patients.

However, it's important to note the small sample size and the need for larger, randomized studies to confirm these results. If replicated, this approach could significantly improve outcomes in a cancer type that has seen progress in recent years. The potential for an HPV-targeted immunotherapy in cervical cancer is particularly exciting given the causative role of HPV in this malignancy.

100% 36-month overall survival (OS) and progression-free survival (PFS) rates in patients fully treated with Versamune® HPV combined with chemoradiation (N=8)
88% (15/17) of patients had a complete metabolic response
IMMUNOCERV Phase 2 clinical trial results presented at ASTRO Annual Meeting 2024

PRINCETON, N.J., Oct. 02, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, today announced that updated data from the IMMUNOCERV Phase 2 clinical trial evaluating Versamune® HPV (formerly PDS0101) with chemoradiation to treat locally advanced cervical cancer were presented at the American Society for Radiation Oncology (ASTRO) Annual Meeting 2024 in an oral presentation by Adam Grippin, M.D., Ph.D., of The University of Texas MD Anderson Cancer Center. The abstract was granted Basic/Translational Science Award from the ASTRO Annual Meeting Steering Committee.

“HPV is responsible for virtually all cervical cancers and presents an opportunity for immunologic targeting1. However, there are currently no FDA-approved HPV-targeted immunotherapies to treat cervical cancer,” said Ann Klopp, M.D., Ph.D., Professor of Radiation Oncology and Head of the Gynecologic Section at MD Anderson. “These data suggest that further investigation is warranted into the safety and efficacy of Versamune® HPV in combination with standard of care in the treatment of locally advanced cervical cancer.”

The IMMUNOCERV Phase 2 clinical trial (NCT04580771) evaluated the efficacy, safety and tolerability of Versamune® HPV in combination with standard-of-care chemoradiotherapy for the treatment of locally advanced cervical cancer. The investigator-initiated study enrolled 17 newly diagnosed high-risk patients with large tumors of at least 5 cm in size. Highlights from the presentation include:

  • All patients received at least 2 doses of Versamune® HPV.
  • Median follow-up was 19 months.
  • 36-month overall survival (OS) rate was 84.4%, and 100% for the eight patients who received all five doses of Versamune® HPV. Historical published data show 36-month OS rate with chemoradiation in this population of approximately 64%.2
  • 36-month progression free survival (PFS) rate was 74.9%, among all patients and 100% for the eight patients who received all five doses of Versamune® HPV. Historical published data show 36-month PFS rate with chemoradiation in this population of approximately 61%.2
  • Complete metabolic response (CMR) was achieved in 15/17 (88%) patients.
  • Versamune® HPV appeared to be safe and well-tolerated. The most common treatment-related toxicities were injection site reactions in twelve patients (71%).

“We are pleased that data from the Phase 2 IMMUNOCERV trial demonstrate compelling clinical activity and a promising safety profile,” said Frank Bedu-Addo, Ph.D., President and Chief Executive Officer of PDS Biotech. “Based on our continued research in various HPV-positive cancers, Versamune® HPV appears to work in combination with a variety of therapeutic agents to generate clinical responses and promote improved survival in patients with minimal toxicity. We look forward to the next steps in the development of Versamune® HPV for locally advanced cervical cancer.”

  1. National Cancer Institute, Cervical Cancer Causes, Risk Factors and Prevention. https://www.cancer.gov/types/cervical/causes-risk-prevention
  2. Rose PG, et al. Concurrent Cisplatin-Based Radiotherapy and Chemotherapy for Locally Advanced Cervical Cancer. N Engl J Med. 1999;340:1144-53.

About PDS Biotechnology
PDS Biotechnology is a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines. The Company plans to initiate a pivotal clinical trial in 2024 to advance its lead program in advanced HPV16-positive head and neck squamous cell cancers. PDS Biotech’s lead investigational targeted immunotherapy Versamune® HPV is being developed in combination with a standard-of-care immune checkpoint inhibitor, and also in a triple combination including PDS01ADC, an IL-12 fused antibody drug conjugate (ADC), and a standard-of-care immune checkpoint inhibitor.

For more information, please visit www.pdsbiotech.com.

Forward Looking Statements
This communication contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnology Corporation (the “Company”) and other matters. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the Company’s management, as well as assumptions made by, and information currently available to, management. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,” “anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,” “intend,” “forecast,” “guidance”, “outlook” and other similar expressions among others. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the Company’s ability to protect its intellectual property rights; the Company’s anticipated capital requirements, including the Company’s anticipated cash runway and the Company’s current expectations regarding its plans for future equity financings; the Company’s dependence on additional financing to fund its operations and complete the development and commercialization of its product candidates, and the risks that raising such additional capital may restrict the Company’s operations or require the Company to relinquish rights to the Company’s technologies or product candidates; the Company’s limited operating history in the Company’s current line of business, which makes it difficult to evaluate the Company’s prospects, the Company’s business plan or the likelihood of the Company’s successful implementation of such business plan; the timing for the Company or its partners to initiate the planned clinical trials for PDS01ADC, Versamune® HPV (formerly PDS0101), PDS0203 and other Versamune® and Infectimune® based product candidates; the future success of such trials; the successful implementation of the Company’s research and development programs and collaborations, including any collaboration studies concerning PDS01ADC, Versamune® HPV, PDS0203 and other Versamune® and Infectimune® based product candidates and the Company’s interpretation of the results and findings of such programs and collaborations and whether such results are sufficient to support the future success of the Company’s product candidates; the success, timing and cost of the Company’s ongoing clinical trials and anticipated clinical trials for the Company’s current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including the Company’s ability to fully fund its disclosed clinical trials, which assumes no material changes to the Company’s currently projected expenses), futility analyses, presentations at conferences and data reported in an abstract, and receipt of interim or preliminary results (including, without limitation, any preclinical results or data), which are not necessarily indicative of the final results of the Company’s ongoing clinical trials; any Company statements about its understanding of product candidates mechanisms of action and interpretation of preclinical and early clinical results from its clinical development programs and any collaboration studies; the Company’s ability to continue as a going concern; and other factors, including legislative, regulatory, political and economic developments not within the Company’s control. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the other risks, uncertainties, and other factors described under “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in the documents we file with the U.S. Securities and Exchange Commission. The forward-looking statements are made only as of the date of this press release and, except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.

Versamune® and Infectimune® are registered trademarks of PDS Biotechnology Corporation.

Investor Contact:
Mike Moyer
LifeSci Advisors
Phone +1 (617) 308-4306
Email: mmoyer@lifesciadvisors.com

Media Contact:
Janine McCargo
6 Degrees
Phone +1 (646) 528-4034
Email: jmccargo@6degreespr.com


FAQ

What were the key results of PDS Biotech's (PDSB) IMMUNOCERV Phase 2 trial for Versamune® HPV?

The IMMUNOCERV Phase 2 trial showed a 36-month overall survival rate of 84.4% for all patients and 100% for those receiving all five doses of Versamune® HPV. The trial also demonstrated a 36-month progression-free survival rate of 74.9% for all patients and 100% for those receiving all five doses. Additionally, 88% of patients achieved a complete metabolic response.

How does Versamune® HPV's efficacy compare to historical data for cervical cancer treatment?

Versamune® HPV showed significantly better results compared to historical data. The trial reported a 36-month overall survival rate of 84.4%, compared to historical data of approximately 64% with chemoradiation alone. Similarly, the 36-month progression-free survival rate was 74.9%, compared to historical data of about 61%.

What was the safety profile of Versamune® HPV in the PDSB IMMUNOCERV Phase 2 trial?

Versamune® HPV appeared to be safe and well-tolerated in the IMMUNOCERV Phase 2 trial. The most common treatment-related toxicities were injection site reactions, occurring in 71% of patients. Overall, the treatment demonstrated a promising safety profile with minimal toxicity.

When and where were the results of PDS Biotech's (PDSB) IMMUNOCERV Phase 2 trial presented?

The updated data from the IMMUNOCERV Phase 2 clinical trial were presented at the American Society for Radiation Oncology (ASTRO) Annual Meeting 2024. The presentation was given by Adam Grippin, M.D., Ph.D., of The University of Texas MD Anderson Cancer Center.

PDS Biotechnology Corporation

NASDAQ:PDSB

PDSB Rankings

PDSB Latest News

PDSB Stock Data

120.40M
36.82M
3.99%
15.07%
13.04%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
PRINCETON